exRNAdisease

General Information

Database ID:

exR0087940

RNA Name:

hsa-miR-22-3p

RNA Type:

miRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

1713914

End Site(bp):

1713935

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
CCDC97	chr19	41310172	41324873	+
AP1S1	chr7	101154456	101161596	+
RCOR1	chr14	102592649	102730561	+
RAB11FIP4	chr17	31391675	31538211	+
PPIF	chr10	79347469	79355334	+
FBXL19	chr16	30923055	30948783	+
FNBP4	chr11	47716494	47767443	-
DCP1A	chr3	53283429	53347586	-
GDAP1	chr8	74321130	74488872	+
WSB2	chr12	118032694	118062430	-
ITGA5	chr12	54395261	54419266	-
IRS2	chr13	109752695	109786583	-
FOXP1	chr3	70952817	71583993	-
TMEM179B	chr11	62787402	62790400	+
ETS1	chr11	128458761	128587558	-
ATP2C1	chr3	130850595	131016712	+
ZNF740	chr12	53180704	53195142	+
CACUL1	chr10	118674167	118755249	-
ATP6V0B	chr1	43974487	43978295	+
ACLY	chr17	41866917	41930542	-
CLASP1	chr2	121337776	121649587	-
PRLR	chr5	35048756	35230487	-
PDPR	chr16	70113626	70162537	+
WWC2	chr4	183099257	183320777	+
TAGLN	chr11	117199370	117207464	+
BCL9	chr1	147541501	147626216	+
GLIS2	chr16	4314761	4339597	+
GBF1	chr10	102245532	102382899	+
PDSS1	chr10	26697701	26746798	+
RANBP2	chr2	108719482	108785809	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001699	chr7	40027197	40041630	+
hsa_circ_0001414	chr4	56277780	56284152	+
hsa_circ_0000733	chr17	1561546	1562030	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC021078.1	chr5	149494314	149504670	-
AL360012.1	chr1	28648600	28648730	+
MALAT1	chr11	65497688	65506516	+
NEAT1	chr11	65422774	65445540	+
NORAD	chr20	36045618	36051018	-
OIP5-AS1	chr15	41283990	41309737	+
SNHG16	chr17	76557764	76565348	+

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.